Global Debut of Innovative Therapies by Sanofi, Boehringer Ingelheim, GSK, and Eli Lilly at CIIE 2025
Sanofi
Pharmaceutical Manufacturer
GSK
Pharmaceutical R&D Manufacturer
Organon
Provider of drugs and treatment solutions
On November 8th, at the 8th China International Import Expo, multinational pharmaceutical companies brought several heavy-weight new products that have just been launched or are about to be launched. Jianshi Jun brings you the latest news from the CIIE scene.
Sanofi
Global Debut of Two Major Cardiovascular Innovation Drugs: Afucitab Tablets and Plerisan Sodium Injection.
Aficamten tablets are second-generation cardiac myosin inhibitors,It is a potential best-in-class treatment for hypertrophic cardiomyopathy, capable of breaking the limitations of traditional drugs and invasive treatments.
The sodium injection of Pluseilan is the world's first siRNA drug targeting the innovative APOC3 mRNA.Expected to break the situation of "no available treatment" for familial chylomicronemia syndrome in China, while ushering in a transformative change in the treatment of severe hypertriglyceridemia.
Eli Lilly
In addition to tirzepatide injection and donanemab injection, Eli Lilly showcased two innovative drugs at this year's CIIE that are about to be approved in China:Imlunestrant, an oral selective estrogen receptor degrader (SERD) in the field of breast cancer; and Mirikizumab, an interleukin-23 inhibitor for the treatment of inflammatory bowel disease.
Boehringer Ingelheim
Highlighted the launch of three innovative new drugs, covering disease areas such as lung cancer, pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis (MASH).
A New Generation of Thrombolytic Drug: Metalyse® (Tenecteplase for Injection)For the treatment of acute ischemic stroke (AIS) within 4.5 hours after onset, marking a new era for thrombolytic therapy in China;
The innovative lung cancer drug Shenghetu® (Zongaitini Tablets) is the world’s first and currently the only approved oral HER2 tyrosine kinase inhibitor,For the treatment of unresectable locally advanced or metastatic non-small cell lung cancer with HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy;
Approved in China in OctoberPulmonary Fibrosis Therapy BoYouWei® (Namicast Tablets)It is the first new therapy approved for the treatment of adult idiopathic pulmonary fibrosis in ten years, and its second indication for the treatment of adult progressive pulmonary fibrosis is currently under priority review.
GSK
GSK has brought several innovative pipeline products in the fields of respiratory, immunology and inflammation, infectious diseases, and oncology, including:
The world's first approved and launched, and the first to conduct Phase III clinical trials in ChinaRespiratory Syncytial Virus (RSV) Vaccine;
Depemokimab is an antisense oligonucleotide (ASO) drug.A drug that can achieve long-acting dosing once every six months is the world's first drug with the potential for "functional cure" of chronic hepatitis B;
Marabrantamab Injection, the world's first anti-BCMA antibody-drug conjugate for multiple myeloma.
Organon
Highlighted the company's therapeutic drugs in the field of lipid management, including the statin product Zocor® (Simvastatin Tablets), the selective intestinal cholesterol absorption inhibitor Ezetrol®, the lipid-lowering combination drug Atozet® (Ezetimibe and Simvastatin Tablets), and a new product launched in China in 2024.Compound lipid-lowering drug Yilituo® (Ezetimibe and Atorvastatin Calcium Tablets (II)),This is the first single-pill fixed-dose combination of ezetimibe and atorvastatin to be approved in China.
By reporter Li Ao
Editor | Jiang Yun, Jia Ting
Operator | Chenxi
Statement: Original content by Jian Shi Ju, please do not reprint without permission.
2025 CIIE | Novartis, Gilead, AstraZeneca, Roche, Merck: New Drug Launch
